In addition, the vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor apatinib reportedly contributes to anti-PD-1 efficiency in mice with colon cancer by enhancing PD-L1 level [27]. This evidence concerns the gene KDR and colonic neoplasm.